RxDoctor Payments Data

Muhammad Bashir, MD

Nephrology · Chico, CANPI 1720081342

Payments from drug & device makers

$37,980in general payments, 2019–2025

Across 160 payments — averaging $237.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$21K
  • AstraZeneca$15K
  • Otsuka America Pharmaceutical, Inc.$392
  • Amgen$201
  • Daiichi Sankyo Inc.$176
  • Kyowa Kirin, Inc.$174
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$34,21690%
  • Travel & lodging$8012%
  • Food & beverage$2,6447%
  • Education$3191%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,980 in reported general payments places this provider in the 85th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$309,548
Medicare patients
270
Services billed
2,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide20$47,835
ProsolParenteral Amino Acid 20% No.1173$25,214
Sevelamer Carbonate62$17,135
LokelmaSodium Zirconium Cyclosilicate17$14,544
Calcium Acetate121$8,386
Potassium Chloride177$6,263
ClinolipidFat Emulsion/Olive/Soy/Phospho28$5,955
Midodrine Hcl33$5,566
Calcitriol287$5,267
Diltiazem 24hr Er (Cd)Diltiazem Hcl194$4,225
Allopurinol200$2,033
Famotidine255$1,831
Colchicine18$1,695
Febuxostat33$1,568
Hydralazine Hcl118$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$145$47,83520 claims
AstraZenecaLokelma$15,104$14,54417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,341 nephrology providers in California.

Other nephrology in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →